Browse News
Filter News
Found 809,160 articles
-
Biogen on Wednesday exceeded analyst profit estimates for the first quarter of 2024 as the biotech’s cost-cutting measures took hold and sales of its Alzheimer’s disease therapy Leqembi started to pick up.
-
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
-
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
-
This is the first round in a series of cuts that will cost 75 people their jobs this year, according to a WARN notice. Employees in other states are affected as well.
-
A report from the Kaiser Family Foundation estimates that the FDA’s recent approval of Novo Nordisk’s Wegovy to reduce the risk of heart attack and stroke in people with cardiovascular disease will open Medicare coverage to one in four beneficiaries with obesity.
-
While Sanofi restructures and parts with employees from U.S. and Belgian sites, a new company in the GLP-1 space emerges from stealth.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
While Bristol Myers Squibb did not explicitly mention China as the company expands and diversifies its manufacturing capacity, Cellares said the BIOSECURE Act would be a boon to its own growth.
-
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
-
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4/24/2024
CureVac N.V. today announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK.
-
Avenue Therapeutics Announces Reverse Stock Split
4/24/2024
Avenue Therapeutics, Inc. today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock.
-
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4/24/2024
CureVac N.V. today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
-
SensaSure Technologies and Verde Bio Holdings Provide Update on Pending Merger
4/24/2024
SensaSure Technologies and Verde Bio Holdings Provide Update on Pending Merger.
-
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
4/24/2024
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR).
-
TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD
4/24/2024
TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from genetic toxicology to residual cancer detection announces the successful acceptance of the standard project submission form (SPSF) by the Organization for Economic Cooperation and Development (OECD).
-
Actym Therapeutics Appoints Thomas Smart as CEO
4/24/2024
Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
-
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
4/24/2024
Synaptogenix, Inc. today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.
-
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
4/24/2024
Gain Therapeutics, Inc. announces positive results from the single ascending dose (SAD) part of its Phase 1 study.
-
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
4/24/2024
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.